JP2021523117A5 - - Google Patents

Info

Publication number
JP2021523117A5
JP2021523117A5 JP2020561727A JP2020561727A JP2021523117A5 JP 2021523117 A5 JP2021523117 A5 JP 2021523117A5 JP 2020561727 A JP2020561727 A JP 2020561727A JP 2020561727 A JP2020561727 A JP 2020561727A JP 2021523117 A5 JP2021523117 A5 JP 2021523117A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
composition
hvr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2020561727A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523117A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/030523 external-priority patent/WO2019213468A1/en
Publication of JP2021523117A publication Critical patent/JP2021523117A/ja
Publication of JP2021523117A5 publication Critical patent/JP2021523117A5/ja
Priority to JP2024022749A priority Critical patent/JP2024045612A/ja
Withdrawn legal-status Critical Current

Links

JP2020561727A 2018-05-04 2019-05-03 慢性蕁麻疹を処置するための方法および組成物 Withdrawn JP2021523117A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024022749A JP2024045612A (ja) 2018-05-04 2024-02-19 慢性蕁麻疹を処置するための方法および組成物

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201862667242P 2018-05-04 2018-05-04
US62/667,242 2018-05-04
US201962788719P 2019-01-04 2019-01-04
US62/788,719 2019-01-04
US201962797817P 2019-01-28 2019-01-28
US62/797,817 2019-01-28
US201962803211P 2019-02-08 2019-02-08
US62/803,211 2019-02-08
US201962806657P 2019-02-15 2019-02-15
US62/806,657 2019-02-15
PCT/US2019/030523 WO2019213468A1 (en) 2018-05-04 2019-05-03 Methods and compositions for treating chronic urticaria

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024022749A Division JP2024045612A (ja) 2018-05-04 2024-02-19 慢性蕁麻疹を処置するための方法および組成物

Publications (2)

Publication Number Publication Date
JP2021523117A JP2021523117A (ja) 2021-09-02
JP2021523117A5 true JP2021523117A5 (cg-RX-API-DMAC7.html) 2022-05-13

Family

ID=68386174

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020561727A Withdrawn JP2021523117A (ja) 2018-05-04 2019-05-03 慢性蕁麻疹を処置するための方法および組成物
JP2024022749A Pending JP2024045612A (ja) 2018-05-04 2024-02-19 慢性蕁麻疹を処置するための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024022749A Pending JP2024045612A (ja) 2018-05-04 2024-02-19 慢性蕁麻疹を処置するための方法および組成物

Country Status (11)

Country Link
US (1) US20210246205A1 (cg-RX-API-DMAC7.html)
EP (1) EP3788078A4 (cg-RX-API-DMAC7.html)
JP (2) JP2021523117A (cg-RX-API-DMAC7.html)
KR (1) KR20210005245A (cg-RX-API-DMAC7.html)
CN (1) CN112384535A (cg-RX-API-DMAC7.html)
AU (1) AU2019262167A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020022236A2 (cg-RX-API-DMAC7.html)
CA (1) CA3099338A1 (cg-RX-API-DMAC7.html)
MX (1) MX2020011377A (cg-RX-API-DMAC7.html)
SG (1) SG11202010911WA (cg-RX-API-DMAC7.html)
WO (1) WO2019213468A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019022912A2 (pt) 2017-05-05 2020-05-26 Allakos Inc. Métodos e composições para tratar doenças oculares alérgicas
EP4180454A4 (en) * 2020-07-10 2024-10-02 Shanghai Jemincare Pharmaceuticals Co., Ltd. Anti-ige engineered antibody and application thereof
KR102803012B1 (ko) * 2022-08-11 2025-04-30 오씨아이 주식회사 석유계 고연화점 피치의 제조방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6715767B2 (ja) * 2013-10-23 2020-07-01 ジェネンテック, インコーポレイテッド 好酸球性疾患の診断及び治療方法
KR20210125114A (ko) * 2013-12-09 2021-10-15 알라코스 인크. 항-Siglec-8 항체 및 그의 사용 방법
JP6825909B2 (ja) * 2014-02-28 2021-02-03 アラコス インコーポレイテッド シグレック−8関連疾患を処置するための方法および組成物
US10604577B2 (en) * 2015-10-22 2020-03-31 Allakos Inc. Methods and compositions for treating systemic mastocytosis

Similar Documents

Publication Publication Date Title
US11512132B2 (en) Anti-PD-L1 antibodies and their use as therapeutics and diagnostics
EP2260057B1 (en) Anti-CD4 antibody dosage regimen for treating autoimmune disease
US12617859B2 (en) Therapeutic anti-CD40 ligand antibodies
JP6454678B2 (ja) pH範囲で結合性が異なる薬物動態改善のための抗TFPI抗体変異体
JP2020503260A5 (cg-RX-API-DMAC7.html)
US20110059082A1 (en) Agent for treating disease
CN102027017A (zh) 一种治疗疾病的试剂
WO2007117600A2 (en) Combination therapy for treating autoimmune diseases
WO2021110107A1 (en) COMBINATION OF BISPECIFIC FUSION PROTEIN AND ANTI-Her2 ANTIBODY FOR TUMOR TREATMENT
JP2020518638A5 (cg-RX-API-DMAC7.html)
US20240092875A1 (en) Sars-cov-2 antibodies for treatment and prevention of covid-19
EP4536704A2 (en) Igf1r antibodies
US20210371519A1 (en) Suppressing IgE-Mediated Allergy by Desensitization with Monovalent Anti-FCeR1a Monoclonal Antibody
JP2022553378A5 (cg-RX-API-DMAC7.html)
HK40015379A (en) Therapeutic anti-cd40 ligand antibodies
HK40005909A (en) Anti-pd-l1 antibodies and their use as therapeutics and diagnostics
HK40005909B (en) Anti-pd-l1 antibodies and their use as therapeutics and diagnostics